ArticleCancer medicine2026
Endometrial Cancer of the Uterine Isthmus: A Cohort Study on Clinicopathological Features and Prognosis.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe study compared the clinicopathologic characteristics and prognosis of patients with uterine isthmus cancer to those with uterine fundus cancer. The aim was to identify risk variables associated with the prognosis of patients with isthmus cancer.
methodsIn the SEER cohort, 584 endometrial cancer patients were included: 91 in the isthmus group and 493 in the fundus group. Data for this retrospective study were collected from the Surveillance, Epidemiology, and End Results (SEER) database and the registry of a provincial hospital. SEER included individuals diagnosed with endometrial cancer between 2000 and 2018. Patients were divided into two groups according to the primary site code for endometrial cancer: Isthmus and fundus. Chi-square tests were used to compare the population characteristics. STROBE Protocol was followed.
resultsIsthmus cancers were younger, more advanced, often non-endometrioid adenocarcinomas, and more likely to receive adjuvant therapy (p < 0.05). The 3-year overall survival rate for isthmus cancer was significantly lower than for fundus cancer (p = 0.016). Uterine isthmus cancer in the hospital cohort accounted for 2.0% (9/455) of the diagnosed endometrial cancers. All patients survived without recurrence or metastasis and were in good physical condition.
conclusionThe research assessed the prognostic impact of the uterine isthmus and the clinical and pathological features of uterine isthmus cancer, and the associated risk factors affecting prognosis. Uterine isthmus cancer demonstrates a higher stage, a stronger tendency for adjuvant therapy, and a more unfavorable prognosis when compared to fundus carcinoma. The international evidence is diverse on this issue.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.